Please assess the completion status of the following clinical trial:

Trial Title: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with WHO group I PAH~* Stable patients with NYHA/WHO functional class I or II~* Age \>18~* Treatment for PAH with parenteral prostanoid (IV epoprostenol, IV or SQ treprostinil) for at least 90 days~* Dose of prostanoid \< 20 ng/kg/min~* mPAP \< 40 mmHg and RAP \<12 mmHg on catheterization~* Clinical decision to convert from parenteral prostanoid therapy to inhaled treprostinil therapy~Exclusion Criteria:~* Concomitant underlying medical condition limiting ability to perform exercise~* Addition of new PAH medication within the past 90 days prior to enrollment~* Participation in a clinical study involving an investigational drug or device \< 4 weeks prior to the screening visit~* Any additional contraindications and precautions specified in the package inserts for treprostinil (Tyvaso) not listed above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: EXPERIMENTAL): This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).